Skip to content

OS Therapies OSTX Deferred Tax Assets, Operating Loss Carryforwards

Deferred Tax Assets, Operating Loss Carryforwards at other companies

CTO
Citius Oncology, Inc.CTOR

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwards.

The official record: OS Therapies’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's deferred tax assets, operating loss carryforwards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's deferred tax assets, operating loss carryforwards?
OS Therapies (OSTX) reported deferred tax assets, operating loss carryforwards of $9.9M in Q4 2025.
What is the long-term trend for OS Therapies's deferred tax assets, operating loss carryforwards?
Over 2 years (2023 to 2025), OS Therapies's deferred tax assets, operating loss carryforwards has grown at a 43.6% compound annual growth rate (CAGR), from $4.8M to $9.9M.